Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.

[1 ]University Medical Center Utrecht, Utrecht, Netherlands;

[2 ]Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;

[3 ]University Medical Center Utrecht, Division of Medical Oncology, Utrecht, Netherlands;

[4 ]University College London Hospitals, London, United Kingdom;

[5 ]Drug Development Department (DITEP), Institut Gustave Roussy, Villejuif, France;

[6 ]OCTIMET Oncology NV, Beerse, Belgium;

[7 ]The Christie NHS Foundation Trust and The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom;

[8 ]University of Oxford, Oxford, United Kingdom;